Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer

por Hakozaki, Taiki
Publicado 2023

PD-L1 expression in small cell lung cancer: should we designate it for assignment?

por Hakozaki, Taiki
Publicado 2021

Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer

por Hakozaki, Taiki
Publicado 2022

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer

por Hirata, Tsuyoshi, Hakozaki, Taiki
Publicado 2023

Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review

por Hakozaki, Taiki, Yomota, Makiko
Publicado 2019

Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer

por Uehara, Yuji, Hakozaki, Taiki
Publicado 2022

Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report

por Hakozaki, Taiki, Okuma, Yusuke, Kashima, Jumpei
Publicado 2018

The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer

por Duttagupta, Sreya, Hakozaki, Taiki, Routy, Bertrand, Messaoudene, Meriem
Publicado 2023

Combined Small and Squamous Transformation in EGFR-mutated Lung Adenocarcinoma

por Hakozaki, Taiki, Kitazono, Miyako, Takamori, Mikio, Kiriu, Takahiro
Publicado 2020

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and...

por Kitagawa, Shingo, Hakozaki, Taiki, Kitadai, Rui, Hosomi, Yukio
Publicado 2020

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report

por Terashima, Yuto, Hakozaki, Taiki, Takeuchi, Susumu, Hosomi, Yukio
Publicado 2022

Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS , MET , FGFR , RET , BRAF , and HER2 alterations

por Uehara, Yuji, Watanabe, Kageaki, Hakozaki, Taiki, Yomota, Makiko, Hosomi, Yukio
Publicado 2022

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis

por Fukuda, Akito, Okuma, Yusuke, Hakozaki, Taiki, Mirokuji, Kie, Yomota, Makiko, Hishima, Tsunekazu, Hosomi, Yukio
Publicado 2022

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combinati...

por Uehara, Yuji, Hakozaki, Taiki, Kitadai, Rui, Narita, Kosuke, Watanabe, Kageaki, Hashimoto, Kana, Kawai, Shoko, Yomota, Makiko, Hosomi, Yukio
Publicado 2022

Cancer Cachexia among Patients with Advanced Non-Small-Cell Lung Cancer on Immunotherapy: An Observational Study with Exploratory Gut Microbiota Analysis

por Hakozaki, Taiki, Nolin-Lapalme, Alexis, Kogawa, Masato, Okuma, Yusuke, Nakamura, Shohei, Moreau-Amaru, Danielle, Tamura, Taichi, Hosomi, Yukio, Takeyama, Haruko, Richard, Corentin, Hosokawa, Masahito, Routy, Bertrand
Publicado 2022

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

por Zhang, Dongming, Shi, Yuequan, Liu, Xiaoyan, Liu, Jia, Xu, Yan, Zhao, Jing, Zhong, Wei, Käsmann, Lukas, Hakozaki, Taiki, Provencio, Mariano, Horita, Nobuyuki, Fukuda, Nobuhiko, Chen, Minjiang, Wang, Mengzhao
Publicado 2022

Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer

por Shao, Changjian, Guo, Kai, Xu, Liqun, Zhang, Yimeng, Duan, Hongtao, Feng, Yingtong, Pan, Minghong, Lu, Di, Ren, Xiaoya, Ganti, Apar Kishor, Hakozaki, Taiki, Han, Jing, Yan, Xiaolong, Ma, Zhiqiang
Publicado 2021

Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients

por Feng, Junnan, Li, Yan, Wei, Bing, Guo, Lei, Li, Weihua, Xia, Qingxin, Zhao, Chengzhi, Zheng, Jiawen, Zhao, Jiuzhou, Sun, Rui, Guo, Yongjun, Brcic, Luka, Hakozaki, Taiki, Ying, Jianming, Ma, Jie
Publicado 2022

Tolerability, safety, and preliminary antitumor activity of fuzuloparib in combination with SHR-1316 in patients with relapsed small cell lung cancer: a multicenter, open-label, tw...

por Xu, Yanjun, Huang, Zhiyu, Fang, Jian, Liu, Anwen, Lu, Hongyang, Yu, Xinmin, Chen, Kaiyan, Xu, Xiaoling, Ma, Xinjing, Shi, Wei, Kim, Young Hak, Hakozaki, Taiki, Addeo, Alfredo, Shen, Yu, Li, Shaorong, Fan, Yun
Publicado 2022

Nivolumab‐induced radiation recall pneumonitis in non‐small‐cell lung cancer patients with thoracic radiation therapy

por Noda‐Narita, Shoko, Naito, Tomoyuki, Udagawa, Hibiki, Goto, Koichi, Miyawaki, Taichi, Mamesaya, Nobuaki, Nakashima, Kazuhisa, Kenmotsu, Hirotsugu, Shimokawaji, Tadasuke, Kato, Terufumi, Hakozaki, Taiki, Okuma, Yusuke, Nakamura, Masaki, Nakayama, Yuko, Watanabe, Hirokazu, Kusumoto, Masahiko, Ohe, Yuichiro, Horinouchi, Hidehito
Publicado 2022